Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD2287 (Imaging agent)
AZD2287 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A: Cohort A1: AZD2287 (Hot only) | EXPERIMENTAL | Participants will receive AZD2287. If eligible for treatment, will receive dose level (DL)1 of AZD2284. |
| Part A: Cohort A2: AZD2275 + AZD2287 (Cold +Hot) | EXPERIMENTAL | Participants will receive DL1 of AZD2275 followed by AZD2287. If eligible for treatment, will receive DL1 of AZD2284. |
| Part A: Cohort A3: AZD2275 + AZD2287 (Cold +Hot) | EXPERIMENTAL | Participants will receive DL2 of AZD2275 followed by AZD2287. If eligible for treatment, will receive DL1 of AZD2284. |
| Part B (Actinium-225 Dose Escalation): DL1: AZD2284 | EXPERIMENTAL | Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL1 of AZD2284. |
| Part B (Actinium-225 Dose Escalation): DL2: AZD2284 | EXPERIMENTAL | Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL2 of AZD2284. |
| Part B (Actinium-225 Dose Escalation): DL3: AZD2284 | EXPERIMENTAL | Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL3 of AZD2284. |
| Part B (Actinium-225 Dose Escalation): DL4: AZD2284 | EXPERIMENTAL | Participants will receive AZD2287 (± AZD2275 as determined in Part A). If eligible for treatment, will receive DL4 of AZD2284. |
| Part B: Cohort E1 | EXPERIMENTAL | Participants will receive dose of AZD2284 determined by the earlier results. Expansion cohort may be opened to further characterize the safety and efficacy of the dose level. |
| Part B: Cohort E2 | EXPERIMENTAL | Participants will receive dose of AZD2284 determined by the earlier results. Expansion cohort may be opened to further characterize the safety and efficacy of the dose level. |
| Name | Type | Description |
|---|---|---|
| AZD2287 | DRUG | Participants will receive AZD2287 |
| AZD2275 | DRUG | Participants will receive AZD2275 |
| AZD2284 | DRUG | Participants will receive AZD2284 |
Main Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1. * Histologically confirmed diagnosis of adenocarcinoma of the prostate without strong clinical suspicion of majority neuroendocrine differentiation. * Must have had prior bilateral orchiectomy and/or ...
AZD2287 is an investigational small molecule being studied for the treatment of metastatic castration-resistant prostate cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
AZD2287 is an imaging agent, and its specific molecular target has not been disclosed in available information. It is being evaluated in a Phase 1 study for metastatic castration-resistant prostate cancer.
AZD2287 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN.
AZD2287 is in Phase 1 clinical development. It is an investigational drug and has not received approval from the FDA or other regulatory agencies.
AZD2287 is being studied in a Phase 1 clinical trial with the identifier NCT06879041. This trial is recruiting participants with metastatic castration-resistant prostate cancer and has an estimated enrollment of 136 patients.
AZD2287 is an imaging agent, while the clinical trial NCT06879041 is studying a related compound, [225Ac]-AZD2284, in patients with metastatic castration-resistant prostate cancer. The two are distinct agents.